- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 28 Days
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2001
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 3,004
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
- Interventions
- Biospecimen Collection, Ipilimumab, Nivolumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 25 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more
- Conditions
- HIV Infections, Hyperlipidemia
- Interventions
- Pravastatin, Darunavir, Ritonavir, Washout
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Obesity, Morbid, Ventilator-Induced Lung Injury, Respiratory Failure
- Interventions
- Esophageal balloon, Intervention Spontaneous Breathing Trial (SBT) and Extubation, Control Spontaneous Breathing Trial and Extubation, Intervention Weaning after Tracheostomy, Control Weaning after Tracheostomy
- Device · Procedure
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Greenville, North Carolina
- Conditions
- Mucopolysaccharidosis III-A
- Interventions
- No intervention
- Other
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 4 Months to 13 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Woburn, Massachusetts
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- Patient Navigator
- Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 1,900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Psoriasis, Metabolic Syndrome
- Interventions
- Not listed
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition
- Interventions
- filgrastim, cyclosporine, methylprednisolone, prednisone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 10 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Celiac Disease
- Interventions
- Vedolizumab
- Drug
- Lead sponsor
- AGA Clinical Research Associates, LLC
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Egg Harbor, New Jersey
- Conditions
- Crohn Disease, Ulcerative Colitis, Irritable Bowel Syndrome, Celiac Disease, Healthy
- Interventions
- Not listed
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Body Composition, Beneficial, Paresis, Impaired Glucose Tolerance
- Interventions
- wt loss, meal pattern, even, skew
- Other · Dietary Supplement
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Pulmonary Embolism
- Interventions
- Macitentan 10mg
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- COVID-19, Long COVID
- Interventions
- MouthLabTM
- Device
- Lead sponsor
- Edith Nourse Rogers Memorial Veterans Hospital
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Bedford, Massachusetts
- Conditions
- PreDiabetes
- Interventions
- Diet and Exercise
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Maternal Obesity Syndrome
- Interventions
- cross-sectional
- Other
- Lead sponsor
- University of Wyoming
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Laramie, Wyoming
- Conditions
- Morbid Obesity
- Interventions
- Surgery
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2035
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Freeman-Sheldon Syndrome, Arthrogryposis Distal Type 2A, Whistling Face Syndrome, Craniocarpotarsal Dysplasia, Craniocarpotarsal Dystrophy, Freeman-Sheldon Syndrome Variant, Sheldon-Hall Syndrome, Arthrogryposis Distal Type 2B, Gordon Syndrome, Arthrogryposis Distal Type 3, Arthrogryposis Distal Type 1, Arthrogryposis, Distal, Type 1A, Arthrogryposis Distal Type 1B, Arthrogryposis, Distal, Craniofacial Abnormalities, Arthrogryposis
- Interventions
- PTSD Checklist-Civilian (PCL-C), Modified Flanagan Quality of Life Scale, Center for Epidemiologic Studies Depression Scale (CES-D), Functional Enquiry (or Review of Systems) Form, Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire, FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI), Medical Records Review
- Other
- Lead sponsor
- Freeman-Sheldon Research Group, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Buckhannon, West Virginia
- Conditions
- Coronary Artery Disease
- Interventions
- AVANDAMET
- Drug
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Murray, Utah
- Conditions
- 22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Sex Chromosome Abnormalities, Cri-du-Chat Syndrome, Angelman Syndrome, Prader-Willi Syndrome, 1p36 Deletion Syndrome
- Interventions
- Not listed
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 20,960 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 16
- States / cities
- San Francisco, California • Camden, New Jersey • Mount Laurel, New Jersey + 10 more
- Conditions
- Depression, Major Depressive Disorder, Weight Gain, Obesity, Metabolic Syndrome
- Interventions
- Reduction of Ultra-processed foods
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hyperphosphatemia, Kidney Disease
- Interventions
- Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
- Interventions
- Brimonidine Tartrate, Placebo Vehicle Gel
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Metabolic Syndrome
- Interventions
- metformin, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee